35 results about "Human epidermal growth factor" patented technology

The invention discloses a gel dressing for treating haemorrhoids and a preparation method of the gel dressing. The gel dressing is prepared from the following raw materials in parts by weight: modified chitosan, multifunctional lipidosome, fructo-oligosaccharide, hyaluronic acid, carbomer, glycerol and recombinant human epidermal growth factors. Chitosan has good film-forming property and antibacterial activity, when haemorrhoids are cracked and bleeding due to long-term constipation, a wound surface is in a high-pH and high-ROS environment, the modified chitosan forms a compact protective film on the ulcerated wound surface, the multifunctional lipidosome with contracted film holes and larger particle size is blocked outside, heparin molecules are grafted on the modified chitosan, and the heparin molecules are grafted on the surface of the wound surface. Recombinant human epidermal growth factors are allowed to pass through, and wound healing is accelerated. When the ulceration part is gradually healed, the pH and ROS level return to normal, the protective film of the modified chitosan is expanded, and the multifunctional liposome is diffused and degraded through the protective film to release the pepper extract, the borneol and the menthol. Fructo-oligosaccharide is added to maintain normal flora balance in the anorectum area.

The invention relates to the technical field of polypeptide detection, and particularly discloses a method for determining the content of human epidermal growth factors in sodium hyaluronate composite gel. The method comprises the following steps: S1, carrying out enzymolysis on sodium hyaluronate in the sodium hyaluronate composite gel by using an enzyme to obtain a test solution; s2, measuring a blank matrix solution containing no human epidermal growth factors, and adding enzyme for enzymolysis to obtain a blank matrix solution; s3, measuring the human epidermal growth factor, and diluting the human epidermal growth factor with the blank matrix solution to obtain a reference substance solution; and S4, detecting the test solution and the reference solution by using a high performance liquid chromatography and an ultraviolet detector, and determining the content of the human epidermal growth factor by using an external standard method. According to the method, hyaluronidase is used for pre-treating the test sample, macromolecular and high-viscosity sodium hyaluronate is subjected to enzymolysis to form micromolecular sugar, the method is compatible with the same liquid chromatography separation system, the content of the human epidermal growth factors in the test sample is measured by adopting an HPLC (High Performance Liquid Chromatography) combined ultraviolet detector, and the method is high in specificity, high in accuracy, low in detection limit and good in repeatability.

The present invention provides an improved method for culturing mesenchymal stem cells and a culture medium used therefor, belonging to the technical field of cell culture. The improved mesenchymal stem cell culture medium provided by the present invention comprises the following exogenous additive components: recombinant human serum albumin, recombinant transferrin, recombinant human epidermal growth factor, basic fibroblast growth factor, platelet-derived growth factor, insulin, L-glutamine, reduced glutathione, β-mercaptoethanol, sodium selenite, penicillin-streptomycin, allicin, heparin and a proliferation promoter; the proliferation promoter comprises paeoniflorin, total saponins of Panax notoginseng, wolfberry polysaccharide and alcohol extract of Saussurea involucrata. By using the above culture medium for culturing mesenchymal stem cells, the cell activity and proliferation ability of mesenchymal stem cells can be significantly increased, the cell viability is increased by more than 50%, and the cell proliferation ability is increased by more than 40%, having great application potential in the culture of mesenchymal stem cells.

The invention relates to mouthwash for promoting postoperative wound healing and a preparation method thereof, and belongs to the technical field of oral care. The invention discloses mouthwash for promoting postoperative wound healing. Comprising 0.5%-2% of a green tea extract, 0.5%-1.5% of a centella asiatica extract, 0.1%-0.5% of a mint extract, 0.1%-0.5% of a lotus leaf extract, 0.1%-0.5% of a spanishneedles herb extract, 5%-15% of a humectant, 0.1%-1% of arginine, 0.1%-1% of a sweetening agent, 0.001%-0.1% of recombinant human epidermal growth factors and the balance of water. The mouthwash is prepared from natural, safe and non-irritant components, so that oral bacteria can be effectively inhibited, and wound healing can be promoted; stability is good, taste is comfortable, and long-term use by patients is facilitated; the oral care solution is expected to be provided for postoperative patients with better quality and more effective oral care solutions, and wound healing and oral health recovery are assisted.

Nucleic acid constructs encoding chimeric antigen receptors (CARs) and truncated human epidermal growth factor receptors (huEGFRt) are described. The encoded CARs include tumor antigen-specific monoclonal antibodies fused to CD8α hinge regions, CD8α transmembrane regions, 4-1BB costimulatory domains, and CD3ζ signaling domains, such as glypican-3 (GPC3)-specific, GPC2-specific, or mesothelin-specific monoclonal antibodies. Separated host cells are also described, such as separated T cells co-expressing the disclosed CARs and huEGFRt. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.

The invention belongs to the technical field of cell culture, and particularly relates to a culture method and application of human astrocytes. According to the culture solution provided by the invention, DMEM (Dulbecco Modified Eagle Medium) and MCDB 131 are mixed according to a specific ratio to form a basic culture medium, and functional additives of HEPES, Glutamax, N2, G-5, B-27, hEGF (Human Epidermal Growth Factor) and the like with accurate concentration and fetal calf serum with proper concentration are matched. The culture solution can effectively improve the vitality and proliferation efficiency of SVGP12 cells, guarantees the growth stability and morphological consistency of the cells, can provide a high-quality and reliable cell source for the application of human astrocytes in the fields of neurobiology research, neurological disease mechanism exploration, drug screening and the like, and has important practical value.

The invention discloses a human epidermal growth factor gel and application thereof, and belongs to the technical field of biomedical materials. The gel is prepared from the following components in parts by mass: 10 to 30 parts of modified calcium hyaluronate gel, 0.01 to 0.5 part of human epidermal growth factor, 5 to 15 parts of narcissus bulb extract, 2 to 8 parts of isopropyl myristate, 5 to 15 parts of glycerol and 40 to 70 parts of purified water. The modified calcium hyaluronate gel is prepared through a specific process, and the process comprises the following steps: reacting sodium hyaluronate with a calcium phosphate precursor, and then adding sodium carboxymethyl cellulose, sodium polyacrylate and a calcium chloride solution containing zinc chloride for treatment. The gel disclosed by the invention has the advantages of overcoming brittle fracture, realizing uniform film formation, being high in compressive strength, being capable of releasing human epidermal growth factors in a pH-responsive manner and improving the transdermal rate of the human epidermal growth factors, also has a synergistic antibacterial ability, can be applied to preparation of skin repair medicaments caused by various reasons, and has a wide application prospect. The skin repairing medicament is suitable for repairing multiple skin injuries and ulceration such as old and rotten legs and burns.

The invention belongs to the technical field of dressing preparation, and discloses a medical fish-source collagen-based slow-release gel dressing for wound repair and a preparation method thereof.The method comprises the steps that after fish-source collagen is dissolved with acetic acid, carboxylated cellulose nanofibers, riboflavin and heparinized human epidermal growth factors are added, physical crosslinking is generated under ultraviolet irradiation, and the fish-source collagen-based slow-release gel dressing is obtained; a network structure with good mechanical strength and porosity is formed, and the drug bearing capacity and the structural stability are enhanced. The prepared hydrogel can be smeared to wounds in different shapes, rapid photo-crosslinking curing is achieved under ultraviolet irradiation, the hydrogel obtained after photo-crosslinking curing can better fit the shapes of the wounds, and wound healing is better protected and promoted; carboxylated cellulose nanofibers and riboflavin are added, so that the gelation speed of the collagen hydrogel can be increased; the hydrogel can effectively load the heparinized human-derived epidermal growth factor and realize slow release of the heparinized human-derived epidermal growth factor, so that the effect of promoting wound healing is achieved.

The invention provides a tumor targeting fusion protein which at least comprises (i) a human epidermal growth factor (hEGF) polypeptide, an hEGF polypeptide variant or a functional fragment thereof, and (ii) an Fc structural domain, an Fc variant or a functional fragment thereof. On one hand, the tumor-targeted fusion protein can resist tumors in a targeted manner, on the other hand, the half-life period of the polypeptide is prolonged, and the tumor-targeted fusion protein has the potential of becoming an anti-tumor therapy drug.

This invention discloses an antibody against human epidermal growth factor 3 (HER3), a method for producing the same, and its use. The HER3 antibody specifically binds to HER3, is endocytotic by cells, and can be used to suppress diseases associated with HER3 expression (including overexpression) or affected by HER3 function, such as tumors.

The invention provides a composition containing neural stem cells, which comprises the following components in parts by mass: 15-20 parts of neural stem cells which are subjected to hypoxia pretreatment and chemical protective agent treatment; 30 to 40 parts of a collagen-sodium alginate composite carrier; 5-8 parts of compound active factors, wherein the compound active factors comprise endostatin, recombinant human epidermal growth factors and superoxide dismutase; and 100 parts of cell protection liquid, wherein the cell protection liquid comprises thioredoxin and nicotinamide. The composition is used for preparing a medicine for treating retina degenerative diseases, and the medicine is an intravitreal injection preparation. The composition synchronously overcomes the three technical bottlenecks of low cell transplantation survival rate, out-of-control differentiation direction and neural network reconstruction disorder through neural stem cell hypoxia pretreatment, active factor compound network, collagen-sodium alginate carrier mechanical adaptation and multi-channel synergistic intervention of a redox protection system.

The application discloses a preparation method and a treatment device of recombinant human epidermal growth factor silk membrane, relates to the technical field of biological products, and is characterized in that a transgenic epidermal growth factor silkworm strain N S EC S The transgenic epidermal growth factor silk biological membrane dressing is prepared through the technical processes of hot pressing and sterilization after the flat plate silk is spun on the two-dimensional plane of a mold. The transgenic epidermal growth factor silk biological membrane prepared by using the technology can greatly maintain the content and activity of the growth factor, greatly saves the time required for preparing the silk structure biological membrane dressing, maintains the natural structure and mechanical properties of the silk, and the preparation process is simpler. Since degumming and silk fibroin extraction are not needed, the treatment cost of the degumming liquid and the silk fibroin extraction liquid is reduced, the pollution to the environment is reduced, and the problem of maintaining the natural structure of the silk and the activity of the epidermal growth factor in the preparation process of the traditional silk membrane is solved. The human epidermal growth factor silk membrane prepared by the method can be applied to the medical fields of wound repair and tissue repair, and has good application potential and value.

The invention discloses a high-stability hEGF sustained-release gel external preparation and a preparation method, and belongs to the technical field of sustained-release gel preparations, and the preparation method comprises the following steps: preparing a poloxamer 407 solution, and preparing a sodium carboxymethyl cellulose solution; adding the sodium carboxymethyl cellulose solution into the poloxamer 407 solution to obtain a mixed solution A, preparing a borneol solution, and adding the borneol solution into the mixed solution A to obtain a mixed solution B; adding the human epidermal growth factor into the mixed solution B to obtain a mixed solution C; filtering and sterilizing to obtain the hEGF sustained-release gel preparation. By adopting a low-temperature gel drug-loading combined process and cooperating with a stable pH system, the biological activity of the human epidermal growth factor can be effectively maintained, it is ensured that the preparation can normally exert the core biological functions of regulating and controlling proliferation, differentiation, migration and the like of related target cells, and the basic requirements for drug efficiency in practical application are met.

The invention discloses a stable human epidermal growth factor injection and a preparation method thereof. The injection consists of a human epidermal growth factor, polysaccharide, a pH regulator, an osmotic pressure regulator, a protein protective agent and water for injection. The osmotic pressure regulator is used for regulating the osmotic pressure of the injection to 270-350mOsmol / kg; the concentration of the human epidermal growth factor is 0.0002-0.003 wt%, the concentration of the polysaccharide is 1.0-50.0 mg / ml, the concentration of the pH regulator is 1.0-50.0 mmol / L, the concentration of the protein protective agent is 0.001-10.0 wt%, and the protein protective agent comprises at least one of non-reducing sugar, polyol, a nonionic surfactant, a metal ion chelating agent, amino acid and peptide. The human epidermal growth factor injection provided by the invention has good stability and is an injectable liquid preparation. The preparation method disclosed by the invention adopts a stirring process protected by inert atmosphere, so that the stability of the injection can be further ensured.

The present application provides a kind of for human epidermal growth factor 2 (HER2) and integrin dual targeting binding protein and its production method and application.Integrin dual targeting binding protein includes HER2 specific nanobody or single chain antibody and integrin polypeptide ligand (RGD).Dual targeting antigen binding protein can target recognition HER2 and integrin protein specifically expressed on the surface of tumor cell, interfere with the expression and signal transduction of HER2 and integrin protein, while inhibiting the expression of EGFR, HER2, HER3, HER4, so as to maximum degree inhibit the growth signal pathway of tumor cell.The dual targeting binding protein can also be used as a drug carrier to deliver drugs directly to the tumor site.The dual targeting binding protein described in the present application can be prepared by E. coli expression system.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.

The invention discloses a human epidermal growth factor temperature-sensitive sustained-release gel as well as a preparation method and application thereof, and belongs to the technical field of biological pharmacy. The preparation method of the human epidermal growth factor temperature-sensitive sustained-release gel comprises the following steps: S1, adding poloxamer and a thickening agent into purified water, and uniformly mixing to form a gel matrix; s2, respectively preparing a human epidermal growth factor solution and a chitosan-sodium tripolyphosphate colloid, and adding the human epidermal growth factor solution into the chitosan-sodium tripolyphosphate colloid for adsorption to obtain the chitosan-sodium tripolyphosphate colloid loaded with the human epidermal growth factor; s3, adding the chitosan-sodium tripolyphosphate colloid loaded with the human epidermal growth factors, a humectant and a stabilizer into the gel matrix, and adjusting the pH value. The gel can realize stable loading and controllable slow release of the human epidermal growth factor, so that the administration frequency and repeated administration operation are reduced, and the gel has important application value in treatment of refractory wounds.

The present invention relates to a transformed Pediococcus pentosaceus strain into which a gene encoding a human epidermal growth factor (EGF) protein is introduced to express and secrete an epidermal growth factor, and a skin-improving cosmetic composition comprising same. According to the present invention, whitening, wrinkle improvement, antioxidant, and skin regeneration effects superior to those of a cosmetic composition comprising commercially available isolated / purified EGF are exhibited. In addition, the present invention facilitates large-scale production of EGF and has economical production costs, thereby providing high competitiveness as a raw material for cosmetic compositions.

Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CAR includes a tumor antigen specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, GPC2-specific or mesothelin-specific monoclonal antibody, fused to a CD8 [alpha] hinge region, a CD8 [alpha] transmembrane region, a 4-1BB co-stimulatory domain, and a CD3 [zeta] signaling domain. Also described are isolated host cells, such as isolated T cells that co-express the disclosed CAR and huEGFRt. The T cells transduced with the disclosed CAR constructs can be used in cancer immunotherapy.

The invention discloses a co-culture solution, a construction method of an in-vitro organ-like model, the in-vitro organ-like model and application of the in-vitro organ-like model, and belongs to the technical field of biological medicine. The DMEM culture medium contains 4-hydroxyethylpiperazine ethanesulfonic acid, L-alanyl-L-glutamine, an N2-additive, a G-5 additive, a B-27 additive, a human epidermal growth factor, penicillin-streptomycin and fetal calf serum, and the MCEB131 culture medium is used for culturing the human epidermal growth factor, the penicillin-streptomycin and the fetal calf serum. The co-culture solution provided by the invention can realize co-culture of human astrocytes SVGP12, human microvascular endothelial cells HMEC-1 and human perineuronal cells HBVP, avoids the interference of cross components of different nutrient solutions on the cells, and improves the stability of an in-vitro organ-like model.

The present invention discloses a culture medium and a culture method for hepatocellular carcinoma organoids. The culture medium comprises RPMI 1640 basal medium and specific additive factors. The composition of the specific additive factors is penicillin-streptomycin 100 μg / mL; human insulin 0.5-5 μM; human epidermal growth factor 50 ng / mL; human transferrin 20-100 nM; Primocin 100 μg / mL; sodium selenite 10-50 nM; sodium pyruvate 0.2-5 mM; fetal bovine serum 1%-10%, v / v; A83-01 5 μM; Y-27632 10 μM. The present invention also provides a culture method for hepatocellular carcinoma organoids, including dissociation and digestion of liver cancer tissues and culturing with this culture medium. The culture medium of the present invention effectively reduces the risk of microbial and mycoplasma contamination in liver cancer culture and improves the success rate of liver cancer organoid culture.

The invention relates to the technical field of sludge conditioners, in particular to a pharmaceutical composition for preventing and treating oropharyngeal mucosal injury caused by radiotherapy and chemotherapy, which is prepared from forsythin, radix ophiopogonis total saponins, L-glutamine, famciclovir, yeast beta-glucan, recombinant human epidermal growth factors, glutathione and glycine. The oral pharyngeal mucosal injury caused by chemoradiotherapy can be prevented and treated. According to the traditional Chinese medicine composition, multiple components have a synergistic effect, and the traditional Chinese medicine composition has prevention and treatment effects and is free of incompatibility and good in tolerance; the mucous membrane adhesive force is enhanced, the administration frequency is reduced, the dosage forms are diversified, different injury degrees and medication scenes are adapted, and the clinical prevention and control requirements are comprehensively met.

The invention discloses a method for determining the binding activity of epidermal growth factors in sodium hyaluronate composite gel. The method comprises the following steps: S1, weighing HE and carrying out enzymolysis to obtain a pre-diluent of a test sample; s2, weighing a human epidermal growth factor activity determination standard substance and redissolving to obtain a linear standard substance solution; s3, diluting the pre-diluent to enable the pre-diluent to be within a detection linear range to obtain a test solution; s4, incubating the standard solution and the test solution; s5, adding a color developing solution after incubation, incubating in a dark place, and adding a stop solution after color development; s6, putting into a microplate reader, measuring absorbance, and recording a result; and S7, drawing a standard curve and analyzing the sample concentration according to the result, and calculating the percentage of the sample concentration in the theoretical value. According to the invention, sodium hyaluronate enzyme is added, so that sodium hyaluronate in the gel can be subjected to enzymolysis, the constraint of the sodium hyaluronate hydrogel with a net structure on EGF in a test sample is relieved, the influence of a double-antibody one-step sandwich method ELISA test on the detection of the EGF content in HE is reduced, and the accuracy of a detection result is improved.

The invention relates to the field of preparation of skin repair medicines, and particularly discloses a pharmaceutical composition for promoting skin regeneration after laser injection and a preparation method of the pharmaceutical composition. The invention discloses a collagen gel, which is prepared from the following active ingredients and auxiliary materials in percentage by weight: 0.1 to 5.0 percent of recombinant human source III type collagen, 0.0001 to 0.01 percent of human epidermal growth factor hEGF, 0.05 to 3.0 percent of witch hazel extract, 2.0 to 10.0 percent of glycerol, 0.1 to 1.5 percent of carbomer, 0.05 to 2.0 percent of chitosan, a proper amount of triethanolamine, 0.01 to 1.0 percent of borneol and the balance of purified water. Carbomer is fully swelled in purified water to construct a gel matrix skeleton, then glycerin, chitosan, a witch hazel extract and borneol are dissolved in a water phase to form a functional solution, and the functional solution is mixed with a swelling matrix to realize primary drug loading; the recombinant human III-type collagen is added into the system before pH regulation to ensure the structural stability, and finally, the human epidermal growth factor hEGF is softly doped after a neutral gel matrix is formed, so that the damage of pH fluctuation and mechanical shear force to biological activity is avoided to the greatest extent.

Provided are a serum-free culture medium and a culturing method for hair follicle stem cells. The serum-free culture medium comprises an MEM non-essential amino acid solution, an MEM vitamin solution, an L-glutamine solution, L-glutathione, sodium selenite, recombinant human serum albumin, recombinant human insulin, recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human platelet-derived growth factor-AB, recombinant human epiregulin, recombinant human catalase, L-ascorbic acid, (+)-α-Tocopheryl acetate, anisomycin, corticosterone, L-carnitine, D-galactose, ethanolamine, linoleic acid, linolenic acid, progesterone, putrescine, and a basal culture medium. The chemical components are clear, exogenous exosome contamination does not occur, rapid in vitro proliferation of HFSCs can be realized, and vacuolization or aging do not occur in multiple cell passagings.

Disclosed is a silk gland recombinant expression vector of silkworm expressing human epidermal growth factor, a preparation method and use thereof. The recombinant expression vector is formed by fusing truncated silk fibroin light chain N-terminal domain, C-terminal domain, optimized human epidermal growth factor and silkworm nuclear polyhedrosis virus enhancer, and removes the redundant part of the extra domain of endogenous silk protein contained in the fusion protein to the maximum extent.

The invention relates to the field of diabetic wound treatment, and particularly discloses a medicine for treating diabetic wound healing and a preparation method thereof.The medicine comprises active ingredients and a pharmaceutically acceptable carrier, the active ingredients are composed of epigallocatechin gallate, recombinant human epidermal growth factors and sitagliptin, and the carrier is composed of chitosan, chitosan and chitosan. The mass ratio of the three components is (20-50): (1-5): (5-15); according to the invention, through innovative compatibility of the active components epigallocatechin gallate (EGCG), recombinant human epidermal growth factor (rhEGF) and sitagliptin, the three components generate a synergistic interaction effect exceeding simple addition; eGCG strongly clears active oxygen and inhibits formation of advanced glycosylation end products, sitagliptin regulates immune response and improves local microenvironment, and clears obstacles for efficient playing of cell proliferation and migration promoting functions of rhEGF, so that drugs can synchronously intervene from three dimensions of oxidation resistance, inflammation resistance and growth promotion.

Disclosed is a silk gland recombinant expression vector of silkworm expressing human epidermal growth factor, a preparation method and use thereof. The recombinant expression vector is formed by fusing truncated silk fibroin light chain N-terminal domain, C-terminal domain, optimized human epidermal growth factor and silkworm nuclear polyhedrosis virus enhancer, and removes the redundant part of the extra domain of endogenous silk protein contained in the fusion protein to the maximum extent.

The present invention relates to new proteins that are specific for human epidermal growth factor kinase receptor 3 (ERB-B3 receptor tyrosine kinase 3, Her3). The Her3 specific proteins of the invention bind with high affinity to human Her3. The invention further refers to Her3 specific proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these Her3 specific binding proteins in medicine, for example, in diagnosis and therapy of Her3 related cancer.